Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai's CARsgen Raises $30 Million for CAR-T Program

publication date: Jan 26, 2016
CARsgen Therapeutics, a Shanghai company developing CAR-T immunotherapies for solid tumors, completed a $30 million Series B round. CARsgen is currently conducting Phase I trials of two CAR-T immunotherapies: one for brain cancer and the other for liver cancer. The company's latest round was led by KTB Ventures, a Korean venture fund, and Jolly Innovation Ventures, which is backed by China's Jolly Pharma. Kaitai Capital and JIC Genesis Fountain Healthcare Ventures participated. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital